AI‑Powered Stock Picks Deliver Exceptional Returns
The ProPicks AI system, launched in November 2023, has generated a cumulative +184.93% return, out‑performing the S&P 500 by +104.28% through August 2026. In August alone the model’s high‑conviction selections posted gains ranging from +26.69% to +40.98%, with the top performers being Haemonetics Corp. (NYSE:HAE) up +26.72% in August and +98.75% since it was first flagged, Merck & Co (NYSE:MRK) up +15.71% in August and +45.23% since selection, and Yubico AB (OM:YUBICO) up +40.98% in August and +109.58% since selection. Other notable August gains included Indosat (IDX:ISAT) +38.42% (+46.52% since pick), Regional Container (SET:RCL) +30.74% (+43.65% since pick), GS Holdings (KOSE:A078930) +28.76% (+56.56% since pick) and Atp Ticari Bilgisayar Ağı ve Elektrik (IBSE:ATATP) +26.69% (+113.43% since pick).
The AI model first identified Haemonetics in September 2025 as a high‑conviction candidate for its Healthcare Heroes and Mid‑Cap Movers strategies. At that time the company traded at only 56 % of its 52‑week high, with a forward price‑to‑earnings multiple of 14.9× and a PEG ratio of 0.34, indicating a large valuation discount. Its Q1 2027 results showed revenue of $339.4 million, earnings per share of $1.14, a gross margin of 58.8 % and an operating margin of 19.4 %, while EBITDA grew 23.6 % year‑over‑year. Citi subsequently upgraded the stock to “Buy” with a $90 price target, reinforcing the upside thesis.
Merck & Co was flagged by the model in January 2026. The stock was trading at 13.9× earnings with a PEG of 0.24, reflecting a deep valuation gap. Q3 results delivered $16.61 billion in revenue, EPS of $2.28, and a 56.3 % year‑over‑year increase in EBITDA. The company’s pipeline includes 80 Phase III trials and a recent $9.2 billion acquisition of Cidara Therapeutics, supporting long‑term growth beyond the Keytruda patent expiry. Merck also offers a 3.2 % dividend yield with a 10.4 % dividend growth rate.
The AI engine evaluates more than 60,000 global equities each month using over 150 quantitative models that blend 15 years of historical financial data, valuation signals and forward‑looking growth metrics. Up to 20 high‑conviction stocks are selected per strategy, rebalanced monthly, and weighted equally to provide a transparent performance benchmark.
InvestingPro members can access the complete August pick list and the underlying rationales at a subscription discount of up to 55 % during the Summer Sale. Subscription pricing is stated as less than $8 per month for new members.